Palatin Technologies is a biopharmaceutical company, developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. The Company’s principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder. Its drug development programs also include melanocortin peptide system program, including PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation.
Type | Public | |
Founded | 1986 | |
HQ | East Windsor, NJ, US | Map |
Website | palatin.com |
USD | |
---|---|
Net income (Q3, 2020) | (5.4m) |
EBIT (Q3, 2020) | (5.7m) |
Market capitalization (19-Jan-2021) | 206.9m |
Closing stock price (19-Jan-2021) | 0.9 |
Cash (31-Mar-2020) | 88.9m |
EV | 118.1m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 27.2k | 11.5k | 24.0k | 3.8k | 6.6k | 4.9m | 8.0m | 10.8m | 26.9m | 10.6m | 9.0m | 34.5k | 97.4k | 20.6k | |||||||||||||
General and administrative expense | 1.1m | 1.0m | 1.3m | 1.1m | 1.0m | 1.1m | 1.0m | 980.1k | 1.2m | 1.1m | 1.4m | 1.1m | 1.2m | 1.4m | 1.4m | 1.2m | 1.3m | 4.8m | 1.5m | 1.6m | 2.4m | 2.0m | 2.1m | 1.8m | 1.8m | 2.4m | 2.1m |
R&D expense | 2.3m | 2.7m | 4.7m | 2.3m | 2.4m | 2.9m | 3.4m | 2.6m | 2.2m | 2.9m | 4.3m | 7.6m | 10.6m | 11.3m | 10.7m | 11.2m | 8.1m | 9.1m | 14.2m | 6.0m | 7.1m | 3.6m | 3.0m | 3.9m | 3.1m | 3.3m | 3.6m |
Operating expense total | 3.4m | 3.7m | 6.1m | 3.4m | 3.4m | 4.0m | 4.5m | 3.6m | 3.4m | 4.0m | 5.7m | 8.7m | 11.8m | 12.6m | 12.1m | 12.4m | 9.4m | 13.8m | 15.7m | 7.7m | 9.5m | 5.7m | 5.1m | 5.8m | 5.0m | 5.7m | 5.7m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 14.9m | 11.9m | 8.8m | 33.5m | 32.9m | 23.5m | 18.6m | 16.7m | 16.7m | 17.8m | 42.7m | 36.7m | 47.5m | 32.0m | 21.8m | 8.9m | 12.1m | 54.5m | 39.7m | 35.0m | 25.7m | 32.6m | 24.7m | 19.8m | 96.7m | 91.5m | 88.9m |
Accounts Receivable | 1.1m | 16.6k | 31.4k | 38.0k | 3.0m | 4.7m | 9.4m | 104.2k | 97.4k | 118.0k | |||||||||||||||||
Prepaid Expenses | 403.1k | 814.7k | 673.4k | 851.8k | 343.9k | 488.2k | 251.7k | 300.2k | 414.6k | 473.6k | 1.5m | 2.0m | 1.8m | 1.7m | 1.5m | 1.0m | 838.3k | 1.1m | 940.0k | 1.3m | 701.5k | 420.6k | 535.1k | 697.2k | 597.9k | 656.6k | 675.4k |
Current Assets | 15.3m | 13.8m | 9.5m | 34.3m | 33.2m | 30.0m | 22.6m | 18.5m | 17.1m | 18.3m | 47.2m | 38.7m | 49.3m | 35.1m | 24.6m | 11.3m | 14.3m | 61.2m | 50.3m | 36.2m | 26.4m | 33.1m | 25.2m | 20.5m | 97.4m | 92.2m | 89.6m |
USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|
Net Income | (17.3m) | (20.9m) | (13.9m) | (17.7m) | (51.7m) | (13.3m) | 24.7m | 35.8m |
Depreciation and Amortization | 949.5k | 111.8k | 111.9k | 117.6k | 43.1k | 33.1k | 56.6k | 58.6k |
Accounts Payable | (202.0k) | 43.8k | (77.4k) | 845.2k | (392.6k) | 837.5k | 672.3k | (1.7m) |
Cash From Operating Activities | (15.5m) | (13.6m) | (12.2m) | (13.4m) | (47.4m) | 12.9m | 1.7m | (21.8m) |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.4m) | (6.0m) | (12.0m) | (10.5m) | (12.1m) | (16.1m) | (4.5m) | (8.1m) | (9.6m) | 794.7k | 3.6m | (5.6m) | (12.4m) | (25.7m) | (38.4m) | (13.1m) | (23.1m) | (26.6m) | 10.6m | 13.6m | 12.9m | (5.7m) | (10.7m) | (16.5m) | (4.5m) | (9.7m) | (15.1m) |
Depreciation and Amortization | 255.0k | 501.1k | 737.1k | 27.5k | 54.8k | 82.4k | 27.2k | 56.6k | 84.3k | 27.6k | 55.2k | 86.8k | 10.7k | 22.2k | 33.2k | 7.6k | 15.3k | 22.9k | 14.6k | 28.9k | 42.6k | 14.0k | 27.9k | 43.5k | 18.3k | 36.5k | 50.8k |
Accounts Payable | (160.7k) | 83.7k | 61.0k | 26.7k | 189.9k | 438.5k | 652.2k | (47.7k) | 93.0k | 300.1k | 1.2m | 2.1m | 2.2m | 1.3m | 676.8k | 445.5k | 4.0m | 529.3k | 482.3k | (847.6k) | (757.7k) | (1.1m) | (1.6m) | (1.7m) | (447.0k) | (369.6k) | 1.1m |
Cash From Operating Activities | (4.0m) | (7.0m) | (10.1m) | (4.7m) | (5.3m) | (8.6m) | (2.0m) | (6.2m) | (7.7m) | 5.7m | 1.4m | (3.9m) | (9.4m) | (23.4m) | (33.7m) | (6.6m) | (17.7m) | 25.8m | 1.4m | (1.6m) | (8.8m) | (5.5m) | (11.0m) | (14.8m) | 54.8m | 49.9m | 47.4m |
USD | Q1, 2012 |
---|---|
Financial Leverage | 1.1 x |
Palatin Technologies has 566 Twitter Followers. The number of followers has increased 5.1% month over month and increased 5.8% quarter over quarter
When was Palatin Technologies founded?
Palatin Technologies was founded in 1986.
Who are Palatin Technologies key executives?
Palatin Technologies's key executives are Carl Spana, John K.A. Prendergast and Stephen T. Wills.
How many employees does Palatin Technologies have?
Palatin Technologies has 18 employees.
What is Palatin Technologies revenue?
Latest Palatin Technologies annual revenue is $60.3 m.
What is Palatin Technologies revenue per employee?
Latest Palatin Technologies revenue per employee is $3.4 m.
Who are Palatin Technologies competitors?
Competitors of Palatin Technologies include Censa Pharmaceuticals, Ortho Dermatologics and Retrophin.
Where is Palatin Technologies headquarters?
Palatin Technologies headquarters is located at 4 Cedarbrook Dr, East Windsor.
Where are Palatin Technologies offices?
Palatin Technologies has an office in East Windsor.
How many offices does Palatin Technologies have?
Palatin Technologies has 1 office.
Receive alerts for 300+ data fields across thousands of companies